Your browser is no longer supported. Please, upgrade your browser.
Settings
CTIC CTI BioPharma Corp. daily Stock Chart
CTIC [NASD]
CTI BioPharma Corp.
Index- P/E- EPS (ttm)-1.80 Insider Own0.90% Shs Outstand42.98M Perf Week-1.20%
Market Cap140.97M Forward P/E- EPS next Y-1.87 Insider Trans0.00% Shs Float39.36M Perf Month-0.61%
Income-54.30M PEG- EPS next Q-0.32 Inst Own43.00% Short Float1.11% Perf Quarter-2.67%
Sales36.50M P/S3.86 EPS this Y71.40% Inst Trans174.51% Short Ratio3.03 Perf Half Y-23.54%
Book/sh1.37 P/B2.39 EPS next Y-48.40% ROA-80.10% Target Price7.50 Perf Year-11.71%
Cash/sh1.74 P/C1.89 EPS next 5Y- ROE-310.40% 52W Range2.70 - 6.48 Perf YTD-19.53%
Dividend- P/FCF- EPS past 5Y44.50% ROI-151.30% 52W High-48.15% Beta0.85
Dividend %- Quick Ratio2.10 Sales past 5Y- Gross Margin96.60% 52W Low24.44% ATR0.11
Employees100 Current Ratio2.10 Sales Q/Q200.00% Oper. Margin- RSI (14)55.61 Volatility2.87% 2.89%
OptionableYes Debt/Eq0.35 EPS Q/Q104.60% Profit Margin- Rel Volume1.89 Prev Close3.28
ShortableYes LT Debt/Eq0.16 EarningsAug 03 AMC Payout- Avg Volume144.59K Price3.36
Recom1.00 SMA202.72% SMA500.19% SMA200-16.41% Volume273,495 Change2.44%
Sep-12-17Initiated Jefferies Buy $7.50
Feb-10-16Downgrade WallachBeth Hold → Sell
Feb-10-16Downgrade Piper Jaffray Overweight → Neutral
Feb-10-16Downgrade Ladenburg Thalmann Buy → Neutral
Nov-09-15Downgrade WallachBeth Buy → Hold $4.50 → $1.60
Aug-05-14Upgrade WallachBeth Hold → Buy $4.50
Mar-19-14Initiated WallachBeth Hold $4.50
Nov-04-13Initiated HC Wainwright Buy $4
Aug-31-17 01:30AM  CTI BioPharma to Present at the BioCentury NewsMakers in the Biotech Industry Conference PR Newswire
Aug-11-17 11:51PM  Edited Transcript of CTIC earnings conference call or presentation 3-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-04-17 03:11AM  CTI BioPharma posts 2Q profit Associated Press +6.41%
Aug-03-17 04:01PM  CTI BioPharma Reports Second Quarter 2017 Financial Results PR Newswire
12:00PM  Investor Network: CTI BioPharma Corp. to Host Earnings Call ACCESSWIRE
Aug-02-17 01:30AM  CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI® for Aggressive B-cell non-Hodgkin lymphoma PR Newswire
Aug-01-17 01:30AM  CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib PR Newswire
Jul-27-17 01:30AM  CTI BioPharma to Report Second Quarter 2017 Financial Results on August 3, 2017 PR Newswire
Jul-24-17 01:30AM  CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors PR Newswire
Jul-13-17 04:05PM  CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have Thrombocytopenia PR Newswire
Jun-15-17 01:30AM  CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX® PR Newswire
Jun-08-17 01:31PM  ETFs with exposure to CTI BioPharma Corp. : June 8, 2017 Capital Cube
Jun-06-17 09:05AM  CTI BioPharma Prices Underwritten Public Offering of $45 Million of Convertible Preferred Stock PR Newswire -20.15%
Jun-05-17 04:02PM  CTI BioPharma Announces Proposed Public Offering Of Convertible Preferred Stock PR Newswire
04:01PM  CTI BioPharma Appoints David R. Parkinson, M.D., Leader in Oncology Clinical Development, to Board of Directors and Announces Board Member Resignations PR Newswire
May-25-17 12:37PM  ETFs with exposure to CTI BioPharma Corp. : May 25, 2017 Capital Cube
May-09-17 08:20AM  Edited Transcript of CTIC earnings conference call or presentation 3-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-08-17 04:22PM  ETFs with exposure to CTI BioPharma Corp. : May 8, 2017 Capital Cube
May-05-17 10:59AM  CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017 Capital Cube
May-03-17 05:20PM  CTI BioPharma reports 1Q loss Associated Press
04:01PM  CTI BioPharma Reports First Quarter 2017 Financial Results PR Newswire
Apr-26-17 04:05PM  CTI BioPharma to Report First Quarter 2017 Financial Results on May 3, 2017 PR Newswire
03:13PM  ETFs with exposure to CTI BioPharma Corp. : April 26, 2017 Capital Cube
Apr-25-17 01:30AM  Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI® Business Wire +7.04%
Mar-31-17 02:29PM  Edited Transcript of CTIC earnings conference call or presentation 2-Mar-17 9:30pm GMT Thomson Reuters StreetEvents
Mar-30-17 04:47PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
Mar-29-17 08:29PM  ETFs with exposure to CTI BioPharma Corp. : March 30, 2017 Capital Cube
08:29PM  ETFs with exposure to CTI BioPharma Corp. : March 30, 2017
Mar-16-17 11:33AM  CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017 Capital Cube
11:33AM  CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017
Mar-14-17 02:37PM  CTI BioPharma Corp. :CTIC-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-13-17 05:29PM  CTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Mar-08-17 01:04PM  CTI BIOPHARMA CORP Financials
01:30AM  CTI BioPharma to Present at the 29th Annual ROTH Conference PR Newswire
Mar-02-17 04:43PM  CTI BioPharma reports 4Q loss Associated Press
04:30PM  CTi Biopharma Corp Earnings Call scheduled for 4:30 pm ET today
04:15PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:01PM  CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results PR Newswire
07:07AM  Q4 2016 CTi Biopharma Corp Earnings Release - After Market Close
Mar-01-17 08:35PM  CTI BioPharma hires new CEO at bizjournals.com
08:35PM  CTI BioPharma hires new CEO American City Business Journals
Feb-27-17 05:01PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
01:30AM  CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO PR Newswire
Feb-23-17 01:30AM  CTI BioPharma to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017 PR Newswire
Feb-10-17 05:04PM  CTI BIOPHARMA CORP Files SEC form 8-K, Other Events
Feb-08-17 01:30AM  CTI BioPharma to Present at the BIO CEO & Investor Conference PR Newswire
Jan-31-17 04:42PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
Jan-24-17 04:39PM  CTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
04:05PM  CTI BioPharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors PR Newswire
Jan-20-17 04:56PM  CTI BIOPHARMA CORP Files SEC form 8-K, Other Events
Jan-10-17 09:15AM  Latest Reports on Recent Market Movers: 3D Systems and CTI BioPharma Accesswire
Jan-09-17 06:07AM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan +20.42%
01:30AM  CTI BioPharma Announces Progress Of Lead Programs And Strategic Objectives For 2017 PR Newswire
Jan-06-17 10:05PM  CTI Biopharma stock revived after FDA ruling, reverse stock split at bizjournals.com +7.62%
Jan-05-17 04:23PM  CTI BIOPHARMA CORP Files SEC form 8-K, Material Modification to Rights of Security Holders +12.34%
12:43PM  Why CTI BioPharma Corp. Stock Popped Today at Motley Fool
01:30AM  CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib PR Newswire
Jan-04-17 10:51AM  ETFs with exposure to CTI BioPharma Corp. : January 4, 2017
08:05AM  CTI BioPharma Corp. breached its 50 day moving average in a Bullish Manner : CTIC-US : January 4, 2017
Jan-03-17 07:03AM  Splits Calendar: CTI BioPharma splits before market open today (1:10 ratio)
Dec-23-16 04:59PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
Dec-21-16 05:31PM  CTI BIOPHARMA CORP Files SEC form 8-K, Material Modification to Rights of Security Holders
Dec-13-16 12:41PM  ETFs with exposure to CTI BioPharma Corp. : December 13, 2016
Dec-11-16 08:08AM  Do Hedge Funds Love Manning and Napier Inc (MN)? at Insider Monkey
Dec-09-16 05:15PM  CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Dec-06-16 10:30AM  PERSIST-2 Phase 3 Study Of Pacritinib Versus Best Available Therapy Shows Encouraging Clinical Activity In High-Risk Patients With Advanced Myelofibrosis In Late-Breaking Session At ASH Annual Meeting PR Newswire +11.42%
Dec-02-16 12:04PM  ETFs with exposure to CTI BioPharma Corp. : December 2, 2016 +9.60%
Dec-01-16 04:01PM  CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium PR Newswire +5.48%
Nov-30-16 05:00PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
Nov-21-16 04:01PM  CTI BioPharma Announces Phase 3 Data from the PERSIST-2 Trial of Pacritinib to be Presented in Late-Breaking Session at ASH Annual Meeting PR Newswire
Nov-10-16 12:12PM  ETFs with exposure to CTI BioPharma Corp. : November 10, 2016
Nov-09-16 11:46AM  CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016 +9.46%
Nov-08-16 04:18PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:16PM  CTI BioPharma reports 3Q loss
04:01PM  CTI BioPharma Reports Third Quarter 2016 Financial Results PR Newswire
Oct-31-16 04:52PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
Oct-24-16 06:05AM  CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definiti
Oct-23-16 04:23PM  5 Biotech Penny Stocks Smart Money Is Piling On at Insider Monkey
Oct-03-16 06:09AM  CTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
01:30AM  CTI BioPharma Announces Retirement Of President And CEO PR Newswire
Sep-29-16 04:48PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
Sep-22-16 01:30AM  CTI BioPharma Granted 180 Day Extension By NASDAQ To Regain Compliance With Minimum Bid Price Rule PR Newswire
Sep-19-16 04:46PM  CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Aug-31-16 05:28PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
Aug-30-16 10:05AM  CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up
Aug-29-16 01:35PM  CTI BioPharma Meets One Of Two Endpoints In Phase 3 Trial +14.86%
06:00AM  CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis PR Newswire
Aug-04-16 06:09PM  CTI BioPharma reports 2Q loss
04:25PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:01PM  CTI BioPharma Reports Second Quarter 2016 Financial Results PR Newswire
Jul-28-16 04:43PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
Jul-20-16 12:18PM  ETFs with exposure to CTI BioPharma Corp. : July 20, 2016
Jun-30-16 04:47PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan -6.87%
Jun-27-16 03:22PM  ETFs with exposure to CTI BioPharma Corp. : June 27, 2016 -15.14%
Jun-10-16 08:32AM  Surging Earnings Estimates Signal Good News for CTI BioPharma (CTIC)
Jun-08-16 08:08AM  Should CTI BioPharma (CTIC) Be On Your Radar Now?
Jun-07-16 01:30AM  Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting PR Newswire
Jun-03-16 03:15PM  ETFs with exposure to CTI BioPharma Corp. : June 3, 2016
May-31-16 04:53PM  CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
May-20-16 11:40AM  ETFs with exposure to CTI BioPharma Corp. : May 20, 2016
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.